R21/Matrix-M™ Malaria Vaccine: a New Tool to Achieve WHO's Goal to Eliminate Malaria in 30 Countries by 2030?

Overview

Journal J Travel Med

Publisher Oxford University Press

Specialties Infectious Diseases
Public Health

Date 2023 Nov 12

PMID 37952234

Authors

Blaise Genton

Affiliations

Soon will be listed here.

Citing Articles

A Nanoparticle Comprising the Receptor-Binding Domains of Norovirus and as a Combination Vaccine Candidate.

Xia M, Huang P, Vago F, Jiang W, Jiang X, Tan M Vaccines (Basel). 2025; 13(1.

PMID: 39852813 PMC: 11769195. DOI: 10.3390/vaccines13010034.

Global Analysis of RTS, S/AS01 Malaria Vaccine Acceptance Rates and Influencing Factors: A Systematic Review.

Ansar F, Azzam A, Rauf M, Ajmal Z, Asad Ullah G, Rauf S Cureus. 2024; 16(5):e60678.

PMID: 38899238 PMC: 11186483. DOI: 10.7759/cureus.60678.

A Self-Assembling Pfs230D1-Ferritin Nanoparticle Vaccine Has Potent and Durable Malaria Transmission-Reducing Activity.

Salinas N, Ma R, McAleese H, Ouahes T, Long C, Miura K Vaccines (Basel). 2024; 12(5).

PMID: 38793797 PMC: 11125772. DOI: 10.3390/vaccines12050546.

Design and Evaluation of Chimeric Circumsporozoite Protein-Based Malaria Vaccines.

Stump W, Klingenberg H, Ott A, Gonzales D, Burns Jr J Vaccines (Basel). 2024; 12(4).

PMID: 38675734 PMC: 11053680. DOI: 10.3390/vaccines12040351.

Current Status of Malaria Control and Elimination in Africa: Epidemiology, Diagnosis, Treatment, Progress and Challenges.

Li J, Docile H, Fisher D, Pronyuk K, Zhao L J Epidemiol Glob Health. 2024; 14(3):561-579.

PMID: 38656731 PMC: 11442732. DOI: 10.1007/s44197-024-00228-2.

References

Datoo M, Natama H, Some A, Bellamy D, Traore O, Rouamba T . Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. Lancet Infect Dis. 2022; 22(12):1728-1736. DOI: 10.1016/S1473-3099(22)00442-X. View

Datoo M, Natama M, Some A, Traore O, Rouamba T, Bellamy D . Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet. 2021; 397(10287):1809-1818. PMC: 8121760. DOI: 10.1016/S0140-6736(21)00943-0. View

Sissoko M, Healy S, Katile A, Omaswa F, Zaidi I, Gabriel E . Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. 2017; 17(5):498-509. PMC: 6803168. DOI: 10.1016/S1473-3099(17)30104-4. View

Collins K, Snaith R, Cottingham M, Gilbert S, Hill A . Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci Rep. 2017; 7:46621. PMC: 5395940. DOI: 10.1038/srep46621. View

. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015; 386(9988):31-45. PMC: 5626001. DOI: 10.1016/S0140-6736(15)60721-8. View